IL258567B2 - A composition comprising a colloidal particle for use in the treatment of haemophilia a, a kit comprising threof and a dosage form threof - Google Patents
A composition comprising a colloidal particle for use in the treatment of haemophilia a, a kit comprising threof and a dosage form threofInfo
- Publication number
- IL258567B2 IL258567B2 IL258567A IL25856718A IL258567B2 IL 258567 B2 IL258567 B2 IL 258567B2 IL 258567 A IL258567 A IL 258567A IL 25856718 A IL25856718 A IL 25856718A IL 258567 B2 IL258567 B2 IL 258567B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- amphipathic lipid
- glycero
- dspe
- factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518172.0A GB201518172D0 (en) | 2015-10-14 | 2015-10-14 | Colloidal particles for use in medicine |
| PCT/EP2016/074759 WO2017064276A1 (en) | 2015-10-14 | 2016-10-14 | Colloidal particles for use in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL258567A IL258567A (en) | 2018-05-31 |
| IL258567B1 IL258567B1 (en) | 2025-04-01 |
| IL258567B2 true IL258567B2 (en) | 2025-08-01 |
Family
ID=55131025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258567A IL258567B2 (en) | 2015-10-14 | 2016-10-14 | A composition comprising a colloidal particle for use in the treatment of haemophilia a, a kit comprising threof and a dosage form threof |
Country Status (15)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122516130A (zh) * | 2019-11-07 | 2026-08-07 | 伊利诺伊大学评议会 | 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法 |
| GB202111758D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111759D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
| GB202111757D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070167359A1 (en) * | 2003-04-15 | 2007-07-19 | Moshe Baru | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU7384994A (en) | 1993-08-06 | 1995-02-28 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
| CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| PT1198490E (pt) | 1999-07-14 | 2006-06-30 | Alza Corp | Lipopolimeros neutros e composicoes liposomais que contem os mesmos |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| BRPI0612843A2 (pt) | 2005-06-29 | 2010-11-30 | The Research Foundation Of State University Of New York | composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação |
| JP2012528846A (ja) | 2009-06-03 | 2012-11-15 | マヨ、ジョン、チャールズ | 深部組織の痛みを治療するための製剤 |
| GB2486371A (en) | 2009-08-21 | 2012-06-13 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| HK1200695A1 (en) | 2012-04-16 | 2015-08-14 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
| ES2887254T3 (es) * | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
-
2015
- 2015-10-14 GB GBGB1518172.0A patent/GB201518172D0/en not_active Ceased
-
2016
- 2016-10-14 CN CN201680073237.XA patent/CN108472246A/zh active Pending
- 2016-10-14 SG SG11201802956RA patent/SG11201802956RA/en unknown
- 2016-10-14 EP EP16781807.9A patent/EP3362039A1/en active Pending
- 2016-10-14 CA CA3036111A patent/CA3036111C/en active Active
- 2016-10-14 BR BR112018007399A patent/BR112018007399A2/pt not_active Application Discontinuation
- 2016-10-14 EA EA201890703A patent/EA201890703A1/ru unknown
- 2016-10-14 SG SG10202010711UA patent/SG10202010711UA/en unknown
- 2016-10-14 WO PCT/EP2016/074759 patent/WO2017064276A1/en not_active Ceased
- 2016-10-14 JP JP2018519423A patent/JP7160678B2/ja not_active Expired - Fee Related
- 2016-10-14 IL IL258567A patent/IL258567B2/en unknown
- 2016-10-14 KR KR1020187013254A patent/KR20180067616A/ko not_active Ceased
- 2016-10-14 US US15/768,381 patent/US20190192664A1/en not_active Abandoned
- 2016-10-14 HK HK18115899.0A patent/HK1256814A1/zh unknown
- 2016-10-14 AU AU2016336929A patent/AU2016336929B2/en not_active Ceased
- 2016-10-14 MX MX2018004445A patent/MX391574B/es unknown
-
2020
- 2020-05-26 US US16/883,338 patent/US20210093721A1/en not_active Abandoned
-
2024
- 2024-06-24 US US18/752,365 patent/US20250170244A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070167359A1 (en) * | 2003-04-15 | 2007-07-19 | Moshe Baru | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018004445A (es) | 2018-08-14 |
| BR112018007399A2 (pt) | 2018-10-16 |
| JP2018535952A (ja) | 2018-12-06 |
| CA3036111A1 (en) | 2017-04-20 |
| JP7160678B2 (ja) | 2022-10-25 |
| US20190192664A1 (en) | 2019-06-27 |
| HK1256814A1 (zh) | 2019-10-04 |
| EP3362039A1 (en) | 2018-08-22 |
| AU2016336929B2 (en) | 2022-09-29 |
| EA201890703A1 (ru) | 2018-11-30 |
| KR20180067616A (ko) | 2018-06-20 |
| CA3036111C (en) | 2023-06-06 |
| MX391574B (es) | 2025-03-21 |
| IL258567A (en) | 2018-05-31 |
| AU2016336929A1 (en) | 2018-05-10 |
| IL258567B1 (en) | 2025-04-01 |
| SG10202010711UA (en) | 2020-12-30 |
| US20250170244A1 (en) | 2025-05-29 |
| CN108472246A (zh) | 2018-08-31 |
| WO2017064276A1 (en) | 2017-04-20 |
| SG11201802956RA (en) | 2018-05-30 |
| US20210093721A1 (en) | 2021-04-01 |
| GB201518172D0 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250170244A1 (en) | Colloidal particles for use in medicine | |
| JP7573582B2 (ja) | Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方 | |
| KR20240040125A (ko) | A형 혈우병 치료용 변형된 콜로이드 입자 | |
| WO2017064289A1 (en) | Colloidal particles for topical administration with therapeutic agent | |
| WO2017064300A1 (en) | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent | |
| US20070167359A1 (en) | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles | |
| US20240358801A1 (en) | Modified colloidal particles for use in the treatment of haemophilia a | |
| US20250064738A1 (en) | Modified colloidal particles for use in the treatment of haemophilia a |